What Happened? Shares of lab services company Charles River Laboratories (NYSE:CRL) jumped 7.5% in the morning session after ...

Shares of Charles River Laboratories International Inc. advanced 9.06% to $163.36 Tuesday, on what proved to be an all-around ...

WILMINGTON, Mass., August 07, 2024 -- (BUSINESS WIRE)--Charles River Laboratories International, Inc. (NYSE: CRL) today reported its results for the second quarter of 2024.

Although the share price is down over three years, Charles River Laboratories International actually managed to grow EPS by 0.7% per year in that time. This is quite a puzzle, and suggests there ...

Charles River Laboratories said on Wednesday that it had received a subpoena from the U.S. Department of Justice over an investigation into the supply of non-human primates from Cambodia, which ...

Charles River Laboratories International had a return on equity of 14.69% and a net margin of 0.52%. The company’s quarterly revenue was down 2.7% compared to the same quarter last year.

Charles River Laboratories' share price has declined over 50% from its 2021 peak, presenting a potential buying opportunity for investors. The CRO company is facing headwinds from COVID's overhang ...

Charles River Laboratories International, Inc. shares have fallen over 20% due to a tougher 2023 outlook and divestment of the avian vaccine business. The company's strong momentum during the ...

The stock’s 50-day moving average is $164.85 and its 200 day moving average is $182.96. Charles River Laboratories International, Inc. has a 1-year low of $150.79 and a 1-year high of $273.32.

Charles River Laboratories International, Inc.'s (NYSE:CRL) price-to-earnings (or "P/E") ratio of 44.8x might make it look like a strong sell right now compared to the market in the United States ...

MEMPHIS, Tenn.--(BUSINESS WIRE)--Charles River Laboratories, International Inc. (NYSE: CRL) announced it has received regulatory approval, in the form of Good Manufacturing Practice (GMP ...

James C. Foster, Chairman, President and Chief Executive Officer of Charles River Laboratories, commented, “Cognate BioServices presents a unique opportunity to expand into a high-growth, value ...